GSA Capital Partners LLP Cuts Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

GSA Capital Partners LLP lowered its stake in RxSight, Inc. (NASDAQ:RXST - Free Report) by 41.2% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 21,084 shares of the company's stock after selling 14,772 shares during the quarter. GSA Capital Partners LLP owned 0.06% of RxSight worth $1,042,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. CWM LLC increased its holdings in RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company's stock valued at $25,000 after buying an additional 371 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in RxSight by 854.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 582 shares of the company's stock valued at $29,000 after buying an additional 521 shares during the period. Quest Partners LLC acquired a new stake in RxSight in the second quarter valued at about $41,000. Amalgamated Bank boosted its position in shares of RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company's stock worth $71,000 after purchasing an additional 207 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of RxSight in the second quarter valued at approximately $156,000. Institutional investors and hedge funds own 78.78% of the company's stock.

RxSight Stock Performance

Shares of RXST traded up $0.89 during trading hours on Friday, reaching $45.05. The stock had a trading volume of 668,980 shares, compared to its average volume of 490,411. The stock has a market capitalization of $1.82 billion, a PE ratio of -54.28 and a beta of 1.19. The company's 50-day moving average is $50.32 and its two-hundred day moving average is $53.27. RxSight, Inc. has a 12 month low of $27.07 and a 12 month high of $66.54.

Insiders Place Their Bets

In related news, Director Jesse Anderson Corley purchased 11,111 shares of the firm's stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average price of $45.37 per share, with a total value of $504,106.07. Following the acquisition, the director now directly owns 468,571 shares of the company's stock, valued at approximately $21,259,066.27. This represents a 2.43 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ilya Goldshleger sold 3,100 shares of the business's stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $52.67, for a total value of $163,277.00. Following the transaction, the insider now directly owns 42,246 shares in the company, valued at $2,225,096.82. This trade represents a 6.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,745 shares of company stock worth $2,240,200. Company insiders own 9.36% of the company's stock.

Analyst Upgrades and Downgrades

RXST has been the subject of several research reports. Oppenheimer decreased their target price on RxSight from $72.00 to $65.00 and set an "outperform" rating for the company in a research report on Tuesday, August 6th. Jefferies Financial Group initiated coverage on shares of RxSight in a research note on Tuesday, October 29th. They issued a "buy" rating and a $72.00 price objective for the company. Wells Fargo & Company dropped their price objective on shares of RxSight from $68.00 to $54.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 6th. Needham & Company LLC reissued a "buy" rating and issued a $66.00 target price on shares of RxSight in a research report on Friday, September 13th. Finally, Stifel Nicolaus reduced their target price on RxSight from $70.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, August 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight currently has an average rating of "Buy" and a consensus price target of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.